Literature DB >> 15494269

Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry.

Tzong-Hae Lee1, Daniel M Chafets, Michael P Busch, Edward L Murphy.   

Abstract

BACKGROUND: Human T-lymphotropic virus type I (HTLV-I) is linked etiologically with adult T cell leukemia/lymphoma and HTLV-I-associated myelopathy/tropical spastic paraparsis (HAM/TSP). Human T-lymphotropic virus type II (HTLV-II) is associated with HAM/TSP and, in HIV coinfected patients only, rare cases of cutaneous T cell lymphoma. Proviral load may be important in the pathogenesis of HTLV-associated disease.
MATERIALS AND METHODS: A real time quantitative PCR assay using SYBR Green intercalation was established. Primers targeting the tax region were standardized against MT2 and MOT cell line DNA for HTLV-I and HTLV-II, respectively. HTLV-I/II copy number was normalized to the amount of cellular DNA by quantitation of the HLA-DQ alpha gene. We measured proviral load in peripheral blood mononuclear cells (PBMCs) in a large cohort of 120 HTLV-I and 335 HTLV-II seropositive former blood donors. We also assessed the intra- and inter-assay reproducibility of the assay.
RESULTS: Proviral load for HTLV-I infected patients ranged from 3.1 x 10(0) to 1.8 x 10(5)copies/10(6) PBMCs with a mean of 1.6 x 10(4) and a median of 3.0 x 10(3). HTLV-I was undetectable in 7 of 120 cases (5.8%). Proviral load for HTLV-II infected patients ranged from 1.1 x 10(0) to 1.0 x 10(6)copies/10(6) PBMCs with a mean of 2.8 x 10(4) and a median of 5.0 x 10(2). HTLV-II was undetectable in 31 out of 335 cases (9.3%).
CONCLUSION: The assay has excellent dynamic range from 10(6) to 10(0)copies/reaction, good intra- and inter-assay reproducibility, and a lower limit of detection of a single copy per reaction. The sensitivity and high dynamic range allow determination of a broad range of HTLV-I/II proviral load in clinical subjects. This assay will facilitate the study of the relationship between proviral load and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494269     DOI: 10.1016/j.jcv.2004.05.016

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  22 in total

1.  Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting.

Authors:  David Yurick; Georges Khoury; Bridie Clemens; Liyen Loh; Hai Pham; Katherine Kedzierska; Lloyd Einsiedel; Damian Purcell
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

2.  HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

Authors:  Estelle Douceron; Zhanna Kaidarova; Paola Miyazato; Masao Matsuoka; Edward L Murphy; Renaud Mahieux
Journal:  J Infect Dis       Date:  2011-11-07       Impact factor: 5.226

3.  Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells.

Authors:  Philip J Norris; Dale F Hirschkorn; Deborah A DeVita; Tzong-Hae Lee; Edward L Murphy
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

Review 4.  Human T cell lymphotropic virus-associated leukemia/lymphoma.

Authors:  Lee Ratner
Journal:  Curr Opin Oncol       Date:  2005-09       Impact factor: 3.645

5.  Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations.

Authors:  Giovanna S Brunetto; Raya Massoud; Emily C Leibovitch; Breanna Caruso; Kory Johnson; Joan Ohayon; Kaylan Fenton; Irene Cortese; Steven Jacobson
Journal:  J Neurovirol       Date:  2014-04-30       Impact factor: 2.643

6.  The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.

Authors:  Steven Kleinman; Melissa R King; Michael P Busch; Edward L Murphy; Simone A Glynn
Journal:  Transfus Med Rev       Date:  2012-05-24

7.  SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness.

Authors:  Vanessa Adaui; Kristien Verdonck; Iván Best; Elsa González; Martín Tipismana; Jorge Arévalo; Guido Vanham; Miguel Campos; Mirko Zimic; Eduardo Gotuzzo
Journal:  J Neurovirol       Date:  2006-12       Impact factor: 2.643

8.  Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.

Authors:  Nyater Ngouth; Maria Chiara Monaco; Lorenzo Walker; Sydney Corey; Ijeoma Ikpeama; Gary Fahle; Irene Cortese; Sanchita Das; Steven Jacobson
Journal:  Viruses       Date:  2022-06-08       Impact factor: 5.818

9.  Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.

Authors:  Shari N Gordon; Anna R Weissman; Valentina Cecchinato; Claudio Fenizia; Zhong-Min Ma; Tzong-Hae Lee; Lorenzo Zaffiri; Vibeke Andresen; Robyn Washington Parks; Kathryn S Jones; Jean Michel Heraud; Maria Grazia Ferrari; Hye Kyung Chung; David Venzon; Renaud Mahieux; Edward L Murphy; Steven Jacobson; Christopher J Miller; Francis W Ruscetti; Genoveffa Franchini
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  Development and validation of a multiplex real-time PCR assay for simultaneous genotyping and human T-lymphotropic virus type 1, 2, and 3 proviral load determination.

Authors:  Britta Moens; Giovanni López; Vanessa Adaui; Elsa González; Lien Kerremans; Daniel Clark; Kristien Verdonck; Eduardo Gotuzzo; Guido Vanham; Olivier Cassar; Antoine Gessain; Anne-Mieke Vandamme; Sonia Van Dooren
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.